Dianthus Therapeutics Banner


Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results

Paula Soteropoulos

Venture Partner, 5AM Ventures
Ms. Soteropoulos has more than 30 years of biopharma industry experience in strategic and operational leadership areas including drug development, global commercialization, manufacturing, new company formation and company building. In addition to a strong focus on rare disease, her career spans a broad range of therapeutic areas including cardiovascular and metabolism, neurology, infectious disease, renal, and transplant and oncology. She currently serves as Chairman of the Board of Ensoma, where she played an instrumental role in launching the company from its venture seed stage.  Ms. Soteropoulos also serves on the Board of Directors for uniQure, Rallybio, and Kyowa Kirin North America and is a strategic advisor to 5AM Ventures and Chiesi Rare Disease. Previously, she served as founding CEO and member of the Board of Directors at Akcea Therapeutics, where she led the company through its IPO and commercial launch of two rare disease medicines. Prior to Akcea, she was Senior Vice President and General Manager of Cardiometabolic and Rare Disease Businesses and Strategic Alliances at Moderna, Inc. Before Moderna, Ms. Soteropoulos spent more than 20 years at Genzyme Corporation where she held positions of increasing responsibility including Vice President and General Manager, Cardiovascular, Rare Diseases. In this role, Ms. Soteropoulos led all aspects of the cardiovascular business from early portfolio prioritization of science and new business development opportunities through commercialization. Ms. Soteropoulos earned an executive management certificate from the University of Virginia – Darden Graduate School of Business Administration and both Bachelor and Master of Science degrees in Chemical and Biochemical Engineering from Tufts University.